2024-513697-22-00招募中3 期
A randomized, open-label, controlled phase III trial comparing the pembrolizumab platinum based chemotherapy combination with pembrolizumab monotherapy in first line treatment of non small-cell lung cancer (NSCLC) patients with PD L1 expression ≥50% on tumor cells : PERSEE TRIAL
Centre Hospitalier Regional Et Universitaire De Brest30 个研究点 分布在 1 个国家目标入组 349 人开始时间: 2024年11月7日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 349
- 试验地点
- 30
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Renaud DESCOURT
Scientific
Centre Hospitalier Regional Et Universitaire De Brest
研究点 (30)
Loading locations...
相似试验
进行中（未招募）
1 期
A trial comparing the pembrolizumab platinum based chemotherapy combination with pembrolizumab monotherapy in first line treatment of non small-cell lung cancer (NSCLC) patientsFirst line, stage IV non small-cell lung cancer (NSCLC) with PD L1 expression on =50 % of tumor cellsMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-002626-86-FRCHRU de Brest292
招募中
3 期
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHNNCT07264075Groupe Oncologie Radiotherapie Tete et Cou780
进行中（未招募）
1 期
Adjuvant Therapy comparing standard endocrine therapy combined with abemaciclib versus standard adjuvant therapy in (clinical or genomic) high risk, hormone receptor positive and HER2 receptor negative, early breast cancer.EUCTR2019-001488-60-DEWestdeutsche Studiengruppe GmbH1,700
招募中
1 期
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+/HER2- early breast cancer (ADAPTlate)HR+/HER2- early breast cancerMedDRA version: 23.0Level: PTClassification code: 10083234Term: Hormone receptor positive breast cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10057654Term: Breast cancer female Class: 100000004864MedDRA version: 23.0Level: PTClassification code: 10083232Term: HER2 negative breast cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10006187Term: Breast cancer Class: 100000004864CTIS2023-509242-35-00WSG Westdeutsche Studiengruppe GmbH2,000
进行中（未招募）
1 期
Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and ImmunotherapySCLC with squamous or nonsquamous histologyMedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003791-12-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.391